Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylamine SCHEMBL2522638 | 0.93 | — | — | |
| Diethylamine SCHEMBL1985592 | 0.93 | — | — | |
| Diethylamine SCHEMBL5142450 | 0.90 | TP53 (0.50) | TP53MCL1CYP2C19ALDH1A1MEN1 | |
| Diethylamine SCHEMBL29021919 | 0.89 | TP53 (0.42) | TP53MCL1 | |
| Diethylamine SCHEMBL28822393 | 0.86 | — | — | |
| Diethylamine SCHEMBL4046893 | 0.86 | — | — | |
| Diethylamine SCHEMBL11565851 | 0.86 | TP53 (0.73) | TP53MCL1CYP2C19ALDH1A1MEN1 | |
| Diethylamine SCHEMBL6311253 | 0.85 | TP53 (0.44) | TP53MCL1ALDH1A1TSHR | |
| Diethylamine SCHEMBL15200806 | 0.84 | TP53 (0.50) | TP53MCL1CYP2C19ALDH1A1MEN1 | |
| Diethylamine SCHEMBL29089953 | 0.83 | MCL1 (0.44) | TP53MCL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3819305-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-05-12 | — | — | EP | disclosed |
| CN-110862399-A | Method for preparing tetrandrine from total tetrandrine | 广西大海阳光药业有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-9585885-B2 | Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-2319599-B1 | METHOD FOR PRODUCING A TARGET SUBSTANCE USING A SIMULATED MOVING BED CHROMATOGRAPHY SEPARATION SYSTEM | DAICEL CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20150315183-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIAVATIVE AND COMPOSITION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2930175-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIVATIVE AND COMPOSITION | Kissei Pharmaceutical Co., Ltd. (JP) | 2015-10-14 | — | — | EP | disclosed |
| CN-102143789-B | Method for producing target substance using simulated moving bed chromatography separation system | DAICEL CHEM | 2013-12-25 | — | — | CN | disclosed |
| CN-101762651-B | Method for measuring abafungin content and impurity by using high performance liquid chromatography | CHONGQING PHARM RES INST CO | 2013-06-12 | — | — | CN | disclosed |
| US-8017017-B2 | Method for producing a target substance using a simulated moving bed chromatography separation system | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| CN-102143789-A | Method for producing a target substance using a simulated moving bed chromatography separation system | DAICEL CHEM | 2011-08-03 | — | — | CN | disclosed |
| US-20110120952-A1 | METHOD FOR PRODUCING A TARGET SUBSTANCE USING A SIMULATED MOVING BED CHROMATOGRAPHY SEPARATION SYSTEM | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2319599-A1 | METHOD FOR PRODUCING A TARGET SUBSTANCE USING A SIMULATED MOVING BED CHROMATOGRAPHY SEPARATION SYSTEM | Daicel Chemical Industries, Ltd. (JP) | 2011-05-11 | — | — | EP | disclosed |
| CN-101762651-A | Method for measuring abafungin content and impurity by using high performance liquid chromatography | CHONGQING PHARM RES INST CO | 2010-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315183-A1 | NOVEL OCTAHYDROPYRIDOQUINAZOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USES FOR SAID DERIAVATIVE AND COMPOSITION | DRD2, DRD1, ADRA1D | TP53 3522/4885MCL1 4187/4885CYP2C19 862/4885 |
| US-11542273-B2 | Amide compound having bet proteolysis-inducing action and medicinal application thereof | BET1, BRD4, PHKB | TP53 30/4885MCL1 29/4885CYP2C19 4834/4885 |
| US-20210284654-A1 | AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF | BET1, BRD4, PHKB | TP53 26/4885MCL1 24/4885CYP2C19 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.